actimmune interferon gamma copay assistance program

The major goals of this project are to develop novel digital biomarkers for the diagnosis and monitoring of progression in individuals with idiopathic Parkinson disease. The Center will work collaboratively with other Udall Centers as well as independently to define the causes of and discover improved treatments for Parkinson’s disease. Goal: To establish a Udall Center at the University of Rochester. This project will validate sensitive measures of how patients feel and function, validate neuroimaging biomarkers of disease progression, and prepare these tools for multi-site use to set the stage for rigorous and efficient clinical trials in CLN3 disease.Ī Udall Center at the University of Rochester Meaningful Outcomes and Multi-Site Readiness for Clinical Trials in Juvenile Neuronal Ceroid Lipofuscinosis She will direct the Institute’s clinical trials unit, be the primary liaison with the Johns Hopkins School of Medicine Institute for Clinical and Translational Research (ICTR), and work closely with the Office of Human Research Administration on human subjects trials oversight and regulatory compliance. Augustine will be responsible for the development, growth, structure and financial management of our clinical trials functions.

Amy Bastian, our chief science officer, to help develop our clinical and translational research strategy and oversee research operations.

She is regarded highly as a clinician, scientist, mentor, and leader.Īt Kennedy Krieger, Dr. She returned to the University of Rochester for parallel fellowships in movement disorders and experimental therapeutics.

Augustine received her A.B., Biological Anthropology from Harvard College, and her Doctorate of Medicine from the University of Rochester and then trained in Pediatric Neurology at Boston Children’s Hospital, serving as Chief Resident.

Actimmune interferon gamma copay assistance program